NCT05974033View on ClinicalTrials.gov

IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)

NANot yet recruitingINTERVENTIONAL
Enrollment

536

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
ICAS - Intracranial Atherosclerosis
Interventions
COMBINATION_PRODUCT

Stenting plus medical therapy

Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.

DRUG

Medical therapy alone

Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.

All Listed Sponsors
lead

Changhai Hospital

OTHER

NCT05974033 - IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT) | Biotech Hunter | Biotech Hunter